一天一家A股公司高管：百济神州生物科技有限公司董事长 欧雷强当资本成为诗行：一位企业掌舵者的价值投资叙事
一、基本信息
欧雷强（John V. Oyler），1969年出生，美国国籍，硕士研究生学历。他是全球创新药企百济神州（北京）生物科技有限公司的联合创始人、执行董事、董事会主席兼首席执行官（2010年至今），也是中国生物医药领域极具影响力的企业家之一。
二、教育背景
1990年：毕业于麻省理工学院（MIT），获理学学士学位（专业未明确提及，但早期职业生涯涉及机械工程与生物领域）。
1996年：毕业于斯坦福大学商学院，获工商管理硕士（MBA）学位。
三、职业生涯经历
欧雷强的职业生涯横跨咨询、创业与生物医药行业，核心经历如下：
1. 咨询行业起步（1990-1997年）
以管理顾问身份加入麦肯锡公司（McKinsey & Company），开启职业生涯。期间积累了战略规划、运营管理与商业咨询经验，为后续创业奠定了基础。
2. 首次进入生物医药行业（1997-1998年）
1997年至1998年，担任Genta Incorporated（纳斯达克上市、肿瘤重点生物制药企业）联席首席执行官。这段经历让他深入接触到生物医药企业的运营模式与研发流程。
3. 第一次创业：电信数据领域（1998-2002年）
1998年，离开Genta后创立Telephia, Inc.（信息商业公司，类似IMS/IQVIA，为决策提供数据服务），并担任总裁。2007年，Telephia以4.49亿美元被尼尔森公司（The Nielsen Company）收购，首次创业获得成功。
4. 回归生物医药：CRO领域创业（2002-2009年）
2002-2004年：担任Galenea Corp（中枢神经系统疾病治疗方法研发企业）首席执行官，积累了生物制药研发管理经验。
2005-2009年：创立BioDuro, LLC（药品开发外包公司，CRO领域），并担任总裁兼首席执行官。2009年，BioDuro以7700万美元被Pharmaceutical Product Development Inc.（PPD）收购。此次创业让他深刻理解了中国生物医药研发的成本优势与人才潜力，为后续进入中国市场埋下伏笔。
5. 联合创立百济神州（2010年至今）
2010年，与王晓东（美国科学院院士、北京生命科学研究所所长）共同创立百济神州（北京）生物科技有限公司，并担任执行董事、董事会主席兼首席执行官。百济神州聚焦肿瘤创新药研发，先后推出百悦泽（泽布替尼，BTK抑制剂）、百泽安（替雷利珠单抗，PD-1抑制剂）等核心产品，成为中国生物医药领域的标杆企业。2019年，欧雷强入选生物技术产业协会（BIO）董事会及其卫生部门理事会，深度参与全球生物医药政策制定。
四、核心成就与荣誉
百济神州发展：带领百济神州从初创企业成长为全球性创新药企，其核心产品百悦泽（泽布替尼）成为全球同类药物领导者，覆盖70多个市场；百泽安（替雷利珠单抗）在中国获批多个适应症，推动中国创新药纳入医保。
行业认可：2019年入选BIO董事会及卫生部门理事会，成为全球生物医药行业的重要参与者；其创业经历被多家媒体报道，成为中国生物医药领域的典型案例。
五、总结
欧雷强的职业生涯以“跨领域、国际化、创新”为核心标签：从咨询到电信，再回归生物医药，每一次转型都抓住了时代机遇；其创业经历覆盖美国与中国市场，深刻理解全球生物医药行业的趋势与需求；作为百济神州的掌舵人，他带领企业实现了从0到1的突破，成为中国创新药走向世界的代表。
John V. Oyler's Professional Profile
I. Basic Information
John V. Oyler, born in 1969, is an American entrepreneur with a master’s degree. He serves as the Co-founder, Executive Director, Board Chairman, and Chief Executive Officer (CEO) of BeiGene (Beijing) Co., Ltd., a global innovative biopharmaceutical company, since 2010. He is widely regarded as one of the most influential entrepreneurs in China’s biopharmaceutical industry.
II. Educational Background
1990: Graduated from the Massachusetts Institute of Technology (MIT) with a Bachelor of Science (B.S.) in an unspecified discipline, though his early career involved mechanical engineering and biology.
1996: Earned a Master of Business Administration (MBA) from Stanford University Graduate School of Business.
III. Professional Career
John Oyler’s career spans consulting, entrepreneurship, and the biopharmaceutical industry, with a clear focus on innovation and global expansion.
1. Consulting: Laying the Foundation (1990–1997)
He began his career as a management consultant at McKinsey & Company, where he gained expertise in strategic planning, operational management, and business consulting—skills that would later underpin his entrepreneurial ventures.
2. Early Biopharmaceutical Experience: Genta Incorporated (1997–1998)
In 1997, Oyler joined Genta Incorporated, a Nasdaq-listed biopharmaceutical company focused on oncology, as Co-Chief Executive Officer (Co-CEO). This role provided him with hands-on experience in the operations and R&D processes of a biotech firm.
3. First Entrepreneurship: Telephia, Inc. (1998–2002)
In 1998, Oyler left Genta to found Telephia, Inc., a data analytics company akin to IMS Health/IQVIA, which provided decision-support data to the pharmaceutical industry. He served as President of Telephia until its acquisition by The Nielsen Company in 2007 for $449 million—a successful exit that marked his first major entrepreneurial achievement.
4. Second Entrepreneurship: BioDuro, LLC (2002–2009)
Between 2002 and 2004, Oyler served as CEO of Galenea Corp, a biotech firm developing treatments for central nervous system (CNS) disorders, further deepening his expertise in biopharmaceutical R&D management.
In 2005, he founded BioDuro, LLC, a contract research organization (CRO) focused on drug development. As President and CEO, he led BioDuro to become a leading player in the CRO space, with its 2009 acquisition by Pharmaceutical Product Development, Inc. (PPD) for $77 million solidifying his reputation as a successful biotech entrepreneur. This experience also exposed him to the cost advantages and talent pool of China’s biopharmaceutical industry, planting the seeds for his future focus on the Chinese market.
5. Co-founding BeiGene: Leading China’s Biopharmaceutical Rise (2010–Present)
In 2010, Oyler partnered with Wang Xiaodong (a member of the U.S. National Academy of Sciences and President of the Beijing Institute of Life Science) to co-found BeiGene (Beijing) Co., Ltd., a company dedicated to developing innovative oncology drugs. As Executive Director, Board Chairman, and CEO, he has led BeiGene from a startup to a global leader in biopharmaceuticals.
Under his leadership, BeiGene has launched two blockbuster products:
BRUKINSA® (zanubrutinib): A BTK inhibitor for lymphoma, which has been approved in over 70 markets worldwide and became the first Chinese-developed oncology drug to receive accelerated approval from the U.S. Food and Drug Administration (FDA).
TEVIMBRA® (tislelizumab): A PD-1 inhibitor for solid tumors, which has been approved in multiple countries, including China, the U.S., and the European Union (EU).
Oyler’s global vision has been instrumental in BeiGene’s expansion: the company established its first U.S. clinical research and production base in New Jersey in 2024 and continues to advance a pipeline of innovative therapies for cancer and other diseases.
In 2019, he was elected to the Board of Directors of the Biotechnology Innovation Organization (BIO) and its Health Section Board, further cementing his role as a key player in the global biopharmaceutical industry.
IV. Key Achievements and Honors
Leadership at BeiGene: Transformed BeiGene from a startup into a global innovative biopharmaceutical company, with products approved in over 70 markets and a pipeline of over 20 clinical-stage candidates.
Industry Recognition: Elected to the BIO Board of Directors in 2019, becoming one of the few Chinese entrepreneurs to hold such a position in a leading global biotech organization.
Global Impact: Led BeiGene to become the first Chinese company to launch an oncology drug (BRUKINSA®) in the U.S. via the accelerated approval pathway, setting a precedent for Chinese biotech firms entering the global market.
V. Summary
John Oyler’s career is defined by cross-industry expertise, international perspective, and a commitment to innovation. From consulting to entrepreneurship in telecom and biopharmaceuticals, each phase of his career has been marked by a focus on solving complex problems and creating value. As the leader of BeiGene, he has not only built a successful global company but also helped position China as a key player in the global biopharmaceutical industry. His experience and vision make him a respected figure among entrepreneurs and industry leaders worldwide.
(All information is based on public sources, including BeiGene’s official announcements, media reports, and industry databases.)
